Key result
An improved understanding of the nitric oxide pathway may lead to the identification of novel medications for the treatment of various neuropsychiatric conditions and brain injuries.
Provides an overview of the nitric oxide pathway and its potential as a therapeutic target for various neuropsychiatric conditions.
Supports NO pathway exploration in neuropsychiatry; leaves open clinical translation pending targeted trials.
The freely diffusible gaseous compound nitric oxide (NO) has recently been discovered to be an important cellular messenger in many organ systems throughout the body. The importance of NO as an intermediary in cell communication in the brain is highlighted by the fact that the excitatory amino acid glutamate, the most abundant central neurotransmitter, is an initiator of the reaction that forms NO. In this article, background information about the discovery of NO, its biochemistry, and a brief summary of some of its peripheral and central actions are given to provide a complete picture of this remarkable novel second messenger. We also discuss how an improved understanding of the NO pathway may lead to the identification of novel medications for the treatment of a number of neuropsychiatric conditions, including memory deficits, pain, drug addiction, seizures, bipolar disorder, psychosis, eating disorders, and the treatment of the sequelae of various brain injuries.
No takes yet. Share an insight, caveat, or question.
Karatinos et al. (1995) conducted a review in Neuropsychiatric conditions. Nitric Oxide Pathway was evaluated. An improved understanding of the nitric oxide pathway may lead to the identification of novel medications for the treatment of various neuropsychiatric conditions and brain injuries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: